By Gina Lee
Investing.com – Hong Kong’s CK Life Sciences International Holdings Inc (HK:) saw its stock jump on the back of Wednesday’s deal to distribute COVID-19 rapid test kits.
The company will distribute the rapid test kits manufactured by Singapore-based medical technology company Biolidics (SI:) in Hong Kong, said a Wednesday press release.
Biolidics received provisional authorization from Singapore’s Health Sciences Authority, and the test kit is already in use in Singapore.
CK Life Sciences’ Hong Kong stocks jumped 12.77% to HK$1.060 by 12:28 AM ET (5:28 AM GMT) on Thursday, whilst Biolidics’ Singapore stocks rose by 3.28%.
Meanwhile, parent company CK Hutchison Holdings (HK:) saw its Hong Kong stocks slide 1.44% to HK$56.28.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.